ProfileGDS5678 / 1452141_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 100% 100% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 113.7743100
GSM967853U87-EV human glioblastoma xenograft - Control 213.5937100
GSM967854U87-EV human glioblastoma xenograft - Control 313.7099100
GSM967855U87-EV human glioblastoma xenograft - Control 413.494299
GSM967856U87-EV human glioblastoma xenograft - Control 513.748100
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 113.7489100
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 213.7184100
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 313.8552100
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 413.7775100
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 113.7953100
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 214.0018100
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 313.8832100
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 413.9889100
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 513.91100